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ARTICLE
Structural effects of the highly protective V127
polymorphism on human prion protein
Laszlo L. P. Hosszu 1, Rebecca Conners1,2,6, Daljit Sangar1, Mark Batchelor 1, Elizabeth B. Sawyer 1,7,
Stuart Fisher3,8, Matthew J. Cliff 4, Andrea M. Hounslow5, Katherine McAuley3, R. Leo Brady 2,
Graham S. Jackson1, Jan Bieschke1, Jonathan P. Waltho 4,5 & John Collinge 1✉
Prion diseases, a group of incurable, lethal neurodegenerative disorders of mammals
including humans, are caused by prions, assemblies of misfolded host prion protein (PrP). A
single point mutation (G127V) in human PrP prevents prion disease, however the structural
basis for its protective effect remains unknown. Here we show that the mutation alters and
constrains the PrP backbone conformation preceding the PrP β-sheet, stabilising PrP dimer
interactions by increasing intermolecular hydrogen bonding. It also markedly changes the
solution dynamics of the β2-α2 loop, a region of PrP structure implicated in prion trans-
mission and cross-species susceptibility. Both of these structural changes may affect access
to protein conformers susceptible to prion formation and explain its profound effect on prion
disease.
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rion diseases, such as bovine spongiform encephalopathy
(BSE) in cattle, scrapie in sheep, and Creutzfeldt-Jakob
disease (CJD), kuru and Gerstmann-Sträussler-Scheinker
(GSS) syndrome in humans, are a group of neurodegenerative
disorders caused by prions, self-replicating β-sheet-rich infectious
polymeric assemblies of misfolded host-encoded cellular prion
protein (PrPC)1–4. Whilst rare, prion diseases are an area of
intense research interest, as it is increasingly recognised that other
degenerative brain diseases, such as Alzheimer’s and Parkinson’s
diseases, also involve the accumulation and spread of aggregates
of misfolded host proteins through an analogous process of see-
ded protein polymerisation2,5–8. Consequently, study of ‘prion-like’
mechanisms has been recognised to have much a wider relevance to
the understanding of neurodegenerative disorders9–11.
PrPC is a cell surface, predominantly α-helical, glycosylpho-
sphatidylinositol (GPI)-anchored glycoprotein that is sensitive to
protease treatment and soluble in detergents1. In contrast, prions
may acquire protease-resistance and are classically designated as
PrPSc (refs. 12,13). PrPSc is found only in prion-infected tissue and
is β-sheet-rich aggregated material, partially resistant to protease
treatment, and insoluble in detergents14.
Transmission experiments to transgenic mice provide strong
supporting evidence that alternative conformers or assembly states
of PrPSc encode multiple prion strains, which differ in their
pathogenic properties2,15. Transgenic mice expressing only human
PrP with either valine or methionine at residue 129 have shown
that this common human polymorphism constrains the propa-
gation of distinct human prion conformers, and the occurrence of
associated patterns of neuropathology consistent with the con-
formational selection model of prion propagation16–20. Hetero-
zygousity at codon 129 is thought to confer resistance to prion
disease by inhibiting homologous protein–protein interactions
essential for efficient prion replication with the presence of
methionine or valine at residue 129 controlling the propagation
of distinct human prion strains2,21. Biophysical measurements
suggest that this powerful effect of residue 129 on prion strain
selection is likely to be mediated via its effect on the conformation
of the disease-associated PrPSc form, or its precursors or on the
kinetics of their formation, as it has no measurable effect on the
structure, folding or stability of PrPC 22.
The acquired prion disease kuru, which was epidemic amongst
the Fore linguistic group of the Papua New Guinea highlands
when first studied in the 1950′s, and which was transmitted
during mortuary feasts, imposed strong genetic selection on the
Fore, essentially eliminating residue 129 homozygotes23. A novel
variant of prion protein, V127, unique to the affected population
in the epicentre of the kuru epidemic, was also identified24. In this
variant, the glycine at residue 127, which is fully conserved
amongst vertebrate PrP primary structures, is substituted by
valine. The V127 polymorphism was found on one copy of the
PRNP gene in unaffected individuals within the population,
suggesting that this polymorphism conferred resistance to prion
disease, having been selected for in response to the kuru epi-
demic23,24. The protection afforded by this polymorphism was
modelled using transgenic mice expressing human PrP25, and
showed that heterozygous mice expressing both alleles containing
glycine and valine at residue 127 (G/V127), echoing the human
resistance genotype, exhibited profoundly reduced susceptibility
to infection with kuru and classical CJD prions. Most impor-
tantly, however, and in complete contrast to the protective effect
of the residue 129 polymorphism, homozygous mice expressing
human PrP with solely valine at residue 127 (V127), showed total
resistance to all inoculated human prion strains. A comparison of
the incubation periods between hemizygous mice expressing
wild-type G127 human PrP only, with heterozygous mice
expressing both G127 and V127 PrP, indicated a dose-dependent
dominant-negative inhibitory effect of V127 PrP on prion pro-
pagation, resulting in prolonged incubation periods and variable
attack rates in heterozygotes25. These data indicated that V127
PrP is intrinsically resistant to prion propagation and can inhibit
propagation involving wild-type (WT) G127 PrP. In essence, this
single amino acid substitution, at a residue completely conserved
in vertebrate evolution, has as potent a protective effect on the
host as a null mutation. Consequently, the structural and
mechanistic basis of the protective effect of the V127 mutation is
of keen interest as it may provide key insights into the mechanism
of prion conformational conversion and recruitment.
As a first step in characterising the effect of this protective
polymorphism on PrP, we undertook a detailed investigation of
the effect of the residue 127 polymorphism on the biophysical
properties of the native cellular PrPC conformation using a
combination of X-ray crystallography, NMR and equilibrium
unfolding. We show that this mutation imposes local changes in
backbone conformation which facilitate formation of inter-
molecular hydrogen bonds between native-state dimers and
imposes conformational restrictions on this region of the protein.
In addition, it significantly alters millisecond timescale con-
formational rearrangements in regions of PrP proposed to be
important in prion transmission26–28. These effects may mod-
ulate the conversion of native PrPC to a disease-associated form
or on pathway intermediates relevant to the disease process, and
provide a mechanistic explanation for the protective effect of this
mutant.
Results
Choice of PrP variants studied. Persons who were exposed to
kuru and survived the epidemic were predominantly hetero-
zygotes at PrP residue 12923. The V127 protective polymorphism
in human PrP was always present on an M129 allele24, conse-
quently our main interest was with the V127/M129 PrP variant.
However, we took the opportunity, given the known biological
effect of the residue 129 polymorphism to also study the V127
variant with valine at residue 129 (V127/V129), and both forms
of wild-type PrP (G127/M129 and G127/V129) with the aim of
dissecting the effects of both of these protective polymorphisms.
V127 PrP structures closely resemble wild-type G127 PrP. To
determine whether the overall structure of PrPC was affected by
the protective V127 variant we crystallised recombinant human
PrP (residues 119–231), with valine at residue 127, (V127/M129
and V127/V129), complexed with the Fab fragment of the anti-
PrP antibody ICSM18, as performed previously with G127/M129
PrP (Supplementary Table 1 and Supplementary Fig. 1)29. The
crystal structures of both V127 variants (V127/M129, 2.3 Å
resolution, pdb 6SV2 and V127/V129, 2.5 Å resolution, pdb
6SUZ) closely resembled that of WT G127/M129 (pdb 2W9E,
Fig. 1a and Supplementary Fig. 2)29. The structured C-terminal
domain (residues 125–225) comprises three α-helices (α1–α3)
and a short, two-stranded, anti-parallel β-sheet (Fig. 1 and Sup-
plementary Fig. 3). Residue 127 immediately precedes the first β-
strand of the β-sheet whereas residue 129 lies within it. The
residues surrounding 127 and 129 are well defined in both crystal
structures (Figs. 2 and 3) and show that the side-chains of both
residues are predominantly located on the protein surface. Nei-
ther the 127 nor 129 polymorphisms substantially perturb the
backbone or sidechain positions, or hydrogen bonding, of resi-
dues within the β-sheet (Fig. 1b and Supplementary Fig. 2a–c).
Both circular dichroism (CD) and heteronuclear NMR spectra
(Supplementary Figs. 4–6) are consistent with the crystal struc-
tures accurately reflecting the solution structure of the proteins.
The global stability and unfolding behaviours of the V127/M129
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and V127/V129 variants (Supplementary Fig. 7 and Supple-
mentary Table 2) are also not significantly affected by the sub-
stitution of valine for glycine at position 127, reflecting the lack of
major structural perturbation.
V127 polymorphism restricts PrP backbone conformation.
Despite the crystal structures being mostly unperturbed by the
V127 polymorphism, a number of localised differences were
identifiable. The most significant area of variation is found
immediately N-terminal of residue 127 (residues 125–127). This
region adopts an essentially identical conformation in both the
V127/M129 and V127/V129 structures, which differs significantly
from WT G127/M129 PrP (Fig. 1b and Supplementary Fig. 2a–c).
In particular, the reduction in the conformational plasticity of the
backbone due to the valine/glycine substitution at position 127
leads to a very different conformation at this point (V127 Phi
angle=−70.5°, c.f. G127=+106.9°), as the WT backbone con-
formation is in a disallowed region of conformational space for
valine. Consequently, the Cα of G126 in V127/M129 PrP is dis-
placed by 2.9 Å, and the Cα of L125 by 2.2 Å (equivalent Cα
atoms of most other surrounding residues are displaced by
0.2–0.3 Å). These Cα atom positions are well defined in both
V127 structures (Figs. 2 and 3).
Furthermore, the V127 polymorphism appears to reduce
conformational variability at residue 127, and concomitantly
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Fig. 1 Effect of the V127 polymorphism on the structure of human PrPC. a V127/M129 (PDB 6SV2 – green) and wild-type G127/M129 human PrP (PDB
2W9E – light blue29) crystal structures, superimposed in cartoon representation. Residues 125–223 are shown. The r.m.s. deviations of backbone heavy
atoms are less than 0.44 Å between these structures. The sidechains of V127 (red) and R164 (blue) are shown as sticks. This figure and the other
structural figures were prepared using PyMOL (PyMOL Molecular Graphics System, Schrödinger, LLC). b Side chain packing in the V127/M129 (green) and
WT G127/M129 (light blue) β-sheets. The PrP backbone immediately preceding residue 127 in V127/M129 PrP is displaced due to the bulkier valine
sidechain at residue 127. The sidechain and backbone positions of residues in the β-sheet are very similar, with the exception of the sidechain of arginine
164 (R164), which due to its close proximity to residue 127 is displaced in the V127 variant. This perturbation (see also Fig. 8) is observed in solution by a
marked chemical shift change in the Nε peak arising from the R164 sidechain group in NMR HSQC spectra (Supplementary Fig. 6). c Four-stranded
intermolecular anti-parallel β-sheet formed between neighbouring V127/M129 PrP molecules (in green and lime green). d Intermolecular β-sheet contacts
in V127/M129 PrP (green) and WT G127/M129 PrP (light blue). The amino acid sidechains of residues found in the intermolecular β-sheet are shown in
stick representation, with the residue 127 and 129 polymorphisms in red and yellow respectively. e, f Intermolecular β-sheet hydrogen bonding in V127/
M129 (e) and G127/M129 PrP (f). Hydrogen bonds stabilising the intermolecular β-sheet are shown as blue dotted lines, between the amide (blue) and
carbonyl (red) groups of the denoted amino acids, with the corresponding distances in Å. The β-sheet interface in the V127/M129 PrP crystal is stabilised
by an additional pair of hydrogen bonds between the carbonyls of G126 and amides of A133 (e). The additional hydrogen bond pair between G126 and A133
is not formed in WT G127/M129 PrP as the hydrogen bond distance is too long (7.7 Å) (f).
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increases structural definition of the β-sheet, as implied by a
comparison of relative B-factors of this region in V127/M129 PrP
when compared with WT G127/M129 PrP. These lower B-factors
extend from L125 to A133, beyond the end of the first strand of
the β-sheet (Fig. 3). In V127/M129 PrP, the average Cα B-factors
for both the N-terminus (residues 126–131; 30 Å2), and β-strand
1 (residues 128–131; 27 Å2) are lower than the average B-factor
for the core secondary structure elements (31 Å2). In contrast, in
wild-type G127/M129 PrP, the corresponding values for both the
N-terminus (46 Å2) and β-strand 1 (42 Å2) are higher than the
average B-factor (39 Å2). As the crystal structures are all
isomorphous with the same crystal packing, we suggest that the
reduction in B-factors is likely due to conformational restriction
introduced by the valine sidechain, and by additional inter-
molecular hydrogen bonding found in the V127 crystals,
described below.
V127 polymorphism extends PrP intermolecular β-sheet.
Notably, dimers between crystallographically-related PrP mole-
cules are observed in the crystals (Fig. 1c). Association is medi-
ated by a short segment of the anti-parallel β-sheet with hydrogen
bonds formed between the first β-strand (residues 128–131) of
each molecule29. This results in the formation of a four-stranded
intermolecular β-sheet between the existing anti-parallel β-sheets
of each PrP molecule, involving close homotypic contacts at L130
(Fig. 1e, f). Similar intermolecular interactions are also observed
in the non-isomorphous crystal structures of sheep30, rabbit31
and human PrP32 in the absence of antibody, and in different
crystallographic space groups (Fig. 4). This suggests that this
interaction is not a crystal packing artefact, and may reflect a
greater biological significance for prion propagation, especially as
residue 129 is protective and crucial to the aetiology and neuro-
pathology of prion disease, and residue 127, which is in close
proximity to the dimer interface, can completely prevent prion
propagation.
The residue 129 polymorphism is accommodated within the
dimer interface without significant perturbations of surrounding
amino acids (Supplementary Fig. 2c, d). In contrast, substitution
by valine at residue 127 results in the formation of an additional
pair of intermolecular hydrogen bonds in both V127 structures,
between the backbone carbonyl and amide groups of G126 and
A133 respectively (Fig. 1e, Supplementary Fig. 2d), due to the
alteration in backbone conformation. This orients the G126
carbonyl group towards the dimer interface, and its hydrogen
bond acceptor A133. In the WT G127/M129 PrP dimer, the
corresponding G126 CO – A133 NH distance is 7.7 Å, as the
carbonyl group of G126 points away from the dimer interface
(Fig. 1f). This additional hydrogen bonding with V127 extends
the β-sheet dimer interface to residues 126–133, thereby
encompassing V127, whereas G127 is not involved in dimer
contacts in WT G127/M129 PrP. The hydrogen bond distances
for these additional H-bonds in the V127 structures (2.8–2.9 Å)
indicate a strong interaction. Also, the hydrogen bonds involving
Y128V127
M129
G126
Fig. 2 The quality of the electron density maps for PrP in the V127/M129
PrP - ICSM-18 Fab complex at 2.3 Å resolution. Residues from the PrP β-
sheet and the V127 polymorphism are shown; 2FO –FC map contoured at 1σ.
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V127 G127
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α2
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Fig. 3 Thermal parameter (B-factor) distribution in human PrP. (a) V127/M129 PrP (b) G127/M129 PrP shown as “putty” representation, as
implemented by PyMOL. The V127/M129 PrP Cα atom B-factors range from 22.7 Å2 to 96.9 Å2 with average values of 38.3 Å2 for the whole protein, and
30.4 Å2 for the core secondary structure elements (residues 128–131 (β-strand 1), 144–154 (α-helix 1), 160–164 (β-strand 2), 174–186 (α-helix 2) and
202–220 (α-helix 3)). The Cα B-factors are depicted on the structure in dark blue (lowest B-factor) through to red (highest B-factor), with the radius of the
ribbon increasing from low to high B-factor. The lowest B-factor is observed in the region of α-helix 2 (α2) and α-helix 3 (α3) where the disulphide bridge
links the two α-helices at residues 179 and 214 (dark blue), with the antibody-binding epitope spanning α-helix 1 also displaying lower than average B-
factors, consistent with the antibody contacts stabilising this region of PrP relative to the overall structure. The largest B-factors are observed in the loop
region linking helices α2 and α3 (red) (α2- α3 loop; residues 191–199), where the electron density clearly shows more disorder than elsewhere in the
structure. In contrast, the B-factors for residues in close proximity to the V127 polymorphism are not unusually high, and all of these residues are clearly
observed in the electron density (see also Fig. 2).
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L130 at the centre of the intermolecular β-sheet interface are
shortened (3.0 Å compared with 3.3 Å) (Fig. 1e, f). Thus, rather
than preventing PrP dimerisation through disruption of inter-
molecular hydrogen bonding33,34, the V127 polymorphism
appears to increase native-state dimer hydrogen bonding.
Increased conformational variability in V127 PrP structures.
Intriguingly, altered conformational variability is observed in key
regions distant from the site of the V127 polymorphism, in par-
ticular the loop linking the second strand of the β-sheet and helix
2 (β2-α2 loop; residues 165–172; Fig. 3). This region, which has
been shown to affect prion cross-species transmissibility26–28,35,36,
is adjacent to the β-sheet, packing against residues N-terminal to
the first β-strand (including residue 127), the β-sheet itself, the C-
terminus of helix 3, and is in close proximity to the disease-
associated residue D17837. The Cα B-factors for residues 169–172
within this loop are higher than the average for the rest of the
protein in both V127 structures (50 vs. 38 Å2 for V127/M129 &
56 vs. 45 Å2 for V127/V129). This contrasts with WT G127/
M129, where these residues are better defined than the average,
according to their B-factors (40 vs. 42 Å2). The B-factors for the
V127 structures are consistent with an alteration in the degree of
conformational exchange in this loop region of the protein
compared to WT PrP, possibly compensating for the reduced
conformational variability observed in the β-sheet region. The
remaining regions of the V127 PrPs display B-factors that are
comparable to WT values.
Altered conformational variability also seen in solution. Cru-
cially, the altered conformational variabilities are also observed in
solution. The effects of the V127 and V129 polymorphisms on the
dynamics of PrP were investigated using NMR relaxation data
(Supplementary Fig. 8), coupled with Modelfree (Fig. 5) and reduced
spectral density analyses (Fig. 6, Supplementary Fig. 9)38,39. The
former uses order parameters (S2) to report internal sub-nanosecond
(ns) motions. S2 values range from 0 for highly flexible to 1 for rigid
systems. The β-sheet and helical regions of all PrP variants exhibit S2
values of 0.8–0.9, typical of structured regions of folded proteins
(Fig. 5). However, a number of residues in structured regions, for
example E168 in V127/M129 and D178 in G127/M129 PrP display
anomalously low S2 values. These are subject to millisecond (ms)
conformational dynamics described below (Fig. 6).
The Modelfree approach also allows a general separation for
each residue of ms conformational dynamics (Rex values) from ns
and sub-ns motions. These ms timescale motions are often
associated with large-scale co-operative conformational changes
and highlight residues that populate low-free energy alternative
conformations. For each of the PrP variants, a number of residues
exhibited Rex values (Fig. 6c). These are concentrated in a
spatially close region, involving the β-sheet (V129/G131/R164),
the β2-α2 loop (M166/E168/Q172) and the C-terminus of helix 3
(I215 T216/Y218/E219/E221; Supplementary Figs. 3, 10 and 11).
The line-broadening of resonances D167, Y169, S170 and N171
beyond detection in the HSQC spectra of all three variants
also likely reflect ms dynamics. The observed conformational
Fig. 4 The interaction of PrP molecules in various PrP crystal structures. a Superposition of human V127 (green), ovine30 (pink), rabbit31 (grey) and
human D178N32 (yellow) PrP dimers from their respective crystal structures. Unlike V127, the other structures were obtained from apo-crystals in the
absence of antibody. The ICSM18 antibody-binding epitope consists of α-helix 1 which is remote from the PrP dimer interface (see b and Supplementary
Fig. 1). b Close up view of the β-sheet dimer interface common to the crystal dimers. The relative orientation of the two interacting PrP molecules in each
structure differs depending on the intermolecular hydrogen-bonding patterns.
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Fig. 5 Degree of order in PrP variants. Order parameters (S2) for G127
(G127/M129), V127 (V127/M129) and V129 (G127/V129) PrP. Residues of
the β1-α1 (residues 134–144) and α2–α3 loops (residues 194–199) display
slightly reduced S2 values (0.6–0.8), reflecting increased flexibility,
commonly observed in loop regions of globular proteins22,71,73, and in
previous studies of PrPC. The N-terminus (residues 119–124) preceding the
β-sheet is mobile and disordered, with low S2 values (0.15–0.5) and a lack
of electron density in the crystal structures. These order parameters are
mapped onto the structures of the PrP variants in Supplementary Fig. 10.
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dynamics are consistent with a proposed interconversion of the
β2-α2 loop between a more populated 310-helix and a type I β-
turn27,30,32,40,41 (Supplementary Fig. 12). The V127 polymorph-
ism results in large increases in ms dynamics for residues G131
and R164 in the β-sheet, and E168 and Q172 in the β2-α2 loop,
but decreases in the C-terminus of helix 3 (215–221; Figs. 6 and
7). In a number of WT PrP crystal structures the sidechain of
R164 forms a pair of hydrogen bonds with the carboxyl group of
E168 (2.5 and 3.1 Å in PDB 2W9E29). The introduction of the
bulkier valine sidechain at residue 127 appears to sufficiently
perturb the side-chain position of R164 such that the interactions
with E168 are essentially removed (the equivalent distances are
3.2 and 3.8 Å; Fig. 8). Significantly, NMR chemical shift changes
in the Nε signal from the R164 sidechain in V127/M129 PrP
reflect this alteration in side-chain orientation, with the Nε being
perturbed by the change in its proximity to the aromatic ring of
Y128 and the change in hydrogen bonding of R164 NH1.
(Supplementary Fig. 6). The loss of these interactions is a likely
source of the increase in the ms dynamics of both residues, which
appears to be disseminated along the rest of the β2-α2 loop, as
residue Q172, the other visible resonance in the β2-α2 loop, also
displays a marked increase.
Similarly, the V129 polymorphism also affects ms dynamics,
however, different residues are affected. V129 increases Rex values
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Fig. 6 Conformational dynamics in the PrP variants. a Reduced spectral density function J(0), describing the amplitude of zero frequency motions in the
PrP variants at 800MHz. Uncharacteristically large J(0) values, such as those exhibited by β-sheet residues (128–131 and 160–164), and G131 and R164 in
V127/M129 PrP in particular, indicate ms – µs dynamics. The dotted lines in the J(0) graphs are two standard deviations greater than the mean J(0) for the
N-terminus (residues 200–210) of helix 3, of the respective variants. b Effect of V127 and V129 polymorphisms on the amplitude of zero frequency J(0)
motions at 800MHz. J(0) changes relative to G127/M129 PrP. Residues which experience significant changes in J(0) due to the V127 substitution include
G131, R164 and E168. V129 results in altered J(0) motions for residues 129 and 131, within the first β-strand, M166, and residue 178, located in helix 2. The
observed changes are due to differential ms conformational dynamics (see c). c PrP ms dynamics (Rex) modelled in the Relax Modelfree analysis. The V127
polymorphism increases ms dynamics (Rex) within the β-sheet (G131/R164) and β2-α2 loop (E168/Q172), and diminishes those at the C-terminus of helix
3. The V129 polymorphism also increases ms dynamics in the first β-strand (V129/G131), and the C-terminus of helix 3. Residues 166 and 172 at either end
of the β2-α2 loop are also perturbed. These Rex values are mapped onto the structure of PrPC (See Fig. 7. and also Supplementary Figs. 10 and 11).
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Fig. 7 Effect of V127 polymorphism on the amplitude of PrP ms dynamics (Rex). The sidechains of residues which experience altered ms dynamics in
V127/M129 PrP, relative to G127/M129 PrP are shown (Fig. 6c), with varying width of backbone and colour. Residues showing increased Rex values in the
V127 variant, such as G131, R164, E168 and Q172, are coloured red, with those showing a reduction, such as Y218, are coloured blue. Those residues for
which a comparison is not possible, due to absence of data are not coloured. The orientation of R164 and E168 sidechains in G127/M129 PrP are shown in
yellow29, illustrating the loss of hydrogen bonding in V127/M129 PrP, caused by a steric clash between V127 and R164 sidechains in the V127 variant. Also
shown is the hydrogen bond between Y169 and D178, showing the close association between the β2-α2 loop and another residue which has a key effect on
the aetiology of human prion disease.
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for G131 and itself (Fig. 6c, Supplementary Figs. 10 and 11). This
alteration in G131 exchange dynamics has recently been observed
in mouse PrP42. In addition, we also observe that the Rex values of
D178 are markedly reduced in the V129 polymorph. This is
illustrated by the reduction of line-broadening of D178 observed
in the HSQC spectra of G127/V129 PrP (Supplementary Fig. 13).
This is notable as the residue 129M/V polymorphism affects
the disease phenotype of the pathogenic D178N mutation which
causes inherited prion disease. D178N is associated with the
clinico-pathological phenotype Fatal Familial Insomnia (FFI)
when residue 129 is methionine, and CJD when it is valine37. In
V127/M129 PrP the D178 HSQC resonance cannot be observed
directly as it is heavily overlapped with that of V127, but an
analysis of the intensity of signals in V127/M129 3D HNCO
NMR spectra indicates that D178 does indeed experience ms
dynamics, to a similar extent as wild-type G127/M129 PrP. This
suggests that the V129 polymorphism alters PrP conformational
variability independently of the 127 mutation.
A number of residues at the C-terminus of helix 3 (I215, Y218,
E219, R220, E221 and S222) experience altered ms dynamics in
V127/M129 compared with G127/V129 PrP. Residues I215/Y218/
E221/S222 are on a face of the helix that interacts with residues in
the β2-α2 loop (Fig. 7, Supplementary Fig. 11). For example,
residues Y218 and S222 closely interact with M166, while I215
and Y218 interact with Q172. In particular, residues Y218 and
E221 are subject to marked increases in Rex values in G127/V129
PrP, whereas in V127/M129 PrP there is a reduction at the
C-terminus.
V127 polymorphism does not perturb PrP stability. To test
whether the variations in dynamics have a substantial effect on
local stability, hydrogen/deuterium exchange rates were obtained
on V127/M129 PrP. The observed rates of hydrogen/deuterium
exchange allow the determination of amide protection factors,
which indicate the extent to which hydrogen bonding and burial
prevents solvent access. The hydrogen/deuterium exchange data
indicate that the protection factors and stabilities of the PrP
secondary structure elements are indistinguishable between
V127/M129 and G127/M129 PrP (Supplementary Fig. 14)22,43.
The protection factors of the secondary structure elements, with
the notable exception of the first strand of the β-sheet and in the
vicinity of the disulphide bond, reflect the equilibrium constant
between native and unfolded states of the protein (KF/U)43. The
majority of residues that display observable protection factors
therefore exchange from the globally unfolded state. This is
also the case with G127/V129 PrP22. The V127 and V129 poly-
morphisms thus do not induce any alternatively folded states in
which the core of the protein is destabilised. This is noteworthy as
the first strand of the β-sheet (where the residue 127 and 129
polymorphisms lie) displays anomalously low protection factors
corresponding to reduced stability (~30 times less than the other
secondary structure elements), suggesting that its stability
might be affected more readily by the protective polymorphisms.
Notably, a number of regions that are subject to the ms con-
formational dynamics affected by both protective polymorphisms
are in areas that do not display measureable hydrogen protection,
for example the β2-α2 loop and the C-terminus of helix 3.
Effect of V127 polymorphism on PrP in vitro fibrilisation. The
lack of major structural perturbation or altered stability of the
V127 variant in comparison to WT PrPC suggests that the
polymorphism may act by primarily affecting the efficiency of
conversion of PrPC to its disease-associated aggregated form. To
assess this we firstly examined the ability of the V127 variant to
fibrilise under partially denaturing conditions. When agitated in
2M GuHCl, PrP can be induced to form amyloid. Binding of the
fluorescent thiazole dye thioflavin T to these β-sheet-rich fibrillar
structures reports their formation, allowing a quantitative analysis
of the kinetics of fibril formation44. We found that although
V127/M129 PrP can be induced to fibrilise within the time scale
of the experiment, it did so with a significantly longer lag-time
than WT G127/M129 PrP (Fig. 9). This is particularly interesting
as substitutions to valine, and other bulky hydrophobic residues
typically promote β-sheet formation and self-association required
for amyloid formation45. These data are however consistent with
previously published data which modelled the effect of the V127
mutation on a mouse PrP background, and which indicated that
the V127 variant is inherently more resistant to fibrilisation than
WT PrP46.
Amplification of protease-resistant PrPSc seed (PMCA).
Although fibrillar material can be generated using these partially
denaturing conditions, the material generated in such reactions
has not been shown to be reliably infectious. In contrast, the
protein misfolding cyclic amplification (PMCA) technique47 has
been shown to amplify infectious and PK-resistant material with
high fidelity. PMCA is a cyclical process where periods of con-
version of substrate PrPC by small amounts of PrPSc “seed” are
interspersed with bursts of sonication. We performed PMCA
reactions using brain homogenate from mice overexpressing WT
G127/M129 PrP (Tg35) WT G127/V129 PrP (Tg152) or V127/
M129 PrP (Tg183). Both WT PrP substrates allowed amplifica-
tion of PK-resistant material. In contrast there was no amplifi-
cation using V127/M129 as substrate (Fig. 10). These results are
consistent with the observed disease characteristics of the vCJD
strain type which propagates most readily with WT PrP with
methionine at residue 129, and which failed to generate protease-
resistant PrP or cause disease in transgenic mice expressing solely
V127/M129 PrP25.
Discussion
This structural and biophysical study was stimulated by the
remarkable effect of the V127 polymorphism on human prion
propagation. Transgenic mouse transmissions show that V127
PrP is incapable of supporting prion transmission and propaga-
tion, consistent with the human clinical resistance data24, and is
even able to inhibit heterologous propagation of wild-type protein
containing glycine at residue 12725. This differs from the residue
129 polymorphism, where similar studies suggest the importance
V127
R164
E168
Fig. 8 Perturbation of the R164 sidechain by V127 in V127 PrP crystals.
Comparison of residue 127, R164 and E168 side-chain positions in WT
G127/M129 (cyan), V127/M129 (green) and V127/V129 PrP (yellow).
Glycine 127 is coloured bright red, with the valine sidechains of residue 127
in V127/M129 and V127/V129 PrP coloured dark red. R164 and E168 in
wild-type G127/M129 PrP are coloured dark blue, and lighter blue in both
V127 variants. In both V127 variants the sidechain of R164 is sufficiently
displaced from its position in the wild-type protein to significantly weaken
the specific, strong (2.5 Å) hydrogen bonding interaction with E168
observed in wild-type G127/M129 PrP.
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of homologous protein interactions in prion propaga-
tion17,18,20,48, and the preferential selection of different prion
strains by PrP molecules with different primary structure as a
result of conformational selection2,16. Unlike the residue 129
polymorphism, no strain switching or strain mutation was
observed with V127, even in the homozygous state, indicating
that it confers complete resistance via the variant protein itself25,
leading to the hypothesis that an altered PrPC fold may be the
cause of resistance to prion disease34. The profound effects that
these mutations have on human prion disease pathogenesis may
provide key insights into the mechanism of prion conversion, and
have a wider relevance to other templated protein mis-folding
diseases, where changing a single amino acid could have a similar
dramatic effect, with potential significance for therapeutic stra-
tegies9,10. The structural consequences of the glycine to valine
substitution at residue 127 on PrPC is therefore of major and wide
potential interest.
Here, we have shown that there is a close similarity in overall
structure between both V127 variants studied (V127/M129 and
V127/V129), and wild-type G127/M129 PrP. Solution spectra
(CD and NMR) confirm that the crystal structures faithfully
reflect the solution structures of the proteins, allowing detailed
analysis of the structural effect of the V127 polymorphism on
PrPC. We find little evidence for a major structural change in the
β-sheet, or α-helices, in contrast to a recent NMR structure which
identified unique features caused by the V127 polymorphism34.
In particular we do not observe any displacement of amino acid
side chains within the β-sheet, which are well defined by the
electron density, and note that this crystal structure satisfies the
inter-residue β-sheet NOE distance constraints used for the NMR
structural study within 0.25 Å34,49, apart from two which are
satisfied within 0.43 Å and 1.03 Å (both to the Hε of Y162).
However, distinct perturbations of key regions which affect
prion transmission and propagation are observed. Specifically, the
V127 substitution reduces the conformational variability of the
protein backbone immediately preceding the first strand of the β-
sheet and radically alters the local backbone conformation. This
facilitates the formation of an additional two intermolecular
hydrogen bonds, which stabilise the native-state dimer associa-
tion observed in the crystals. This dimeric association has been
observed in a number of different PrP structures crystallised in
the absence of antibody30–32 (Fig. 4). In these, the PrP β-sheet
interface is composed of two intermolecular hydrogen bonds, as
in WT G127/M129 PrP29. The V127 dimer interface presented
here is unique in both the length of the β-sheet interface and
number of hydrogen bonds (4), and argues against the proposal
that V127 disfavours native-state dimerisation, by reducing main-
chain hydrogen-bond interactions33,34.
Formation of the intermolecular β-sheet has been proposed as
a possible initiation point for β-sheet-mediated oligomerisation to
explain the genetic susceptibility and prion strain selection
determined by the polymorphic residue 129 in human prion
disease23,29,30,32. If β-strand interactions in this region of the
protein mediate PrP interactions during PrPSc formation, then
the packing and geometry of this segment of the chain would
have a strong selective effect on conformation, and also pro-
ductive prion propagation29. No displacement of the protein
backbone or stabilisation of the PrPC dimer interface is caused by
the residue 129 polymorphism22,32, which may explain the
marked effect of the V127 polymorphism on prion pathogenesis.
The PrPC dimer interaction does not appear to be a crystal
packing artefact as endogenous PrPC dimers have been detected
in N2a cells and purified brain fractions50,51 with the dimerisa-
tion region mapped to the hydrophobic domain of PrP (residues
112–133)52. PrPC dimerisation inhibits PrPSc accumulation and
prion replication53,54, and has a dominant-negative inhibitory
effect on the conversion of monomeric PrPC54. These findings
suggest that it may be possible to halt prion formation by stabi-
lising PrPC dimers. Given the strengthened dimer association seen
in the V127 crystals this may be one aspect of the protective
mechanism of the V127 mutant. The conformational restriction
imposed by the V127 polymorphism may also be sufficient to
Fig. 10 Western blot indicating the presence of PK-resistant material in
PMCA reaction (+) and non-sonicated control (−) samples of PrPSc
amplified with Tg35 (huPrP G127/M129), Tg152 (huPrP G127/V129) and
Tg183 (huPrP V127/M129) brain homogenate as substrate. In each case,
a small amount of seed can be detected in the non-sonicated control
samples with varying levels of amplification observed in the reactions with
different substrates. Of note is the lack of amplification with V127/M129
PrP (Tg183) as substrate.
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Fig. 9 Quantitative analysis of the effect of V127 on PrP fibril formation.
a Formation of amyloid fibrils as reported by increasing Thioflavin T (ThT)
fluorescence. The lines superimposed on the data are non-linear curve fits
to Eq. (2), as described in the Methods section. b, c Fibrillogenesis of V127/
M129 PrP occurs with significantly longer mean half- and lag times in
comparison to WT G127/M129 PrP (P≤ 0.01, paired t-test). Centre lines
show the medians for each data set; box limits indicate the 25th and 75th
percentiles as determined by R software (http://shiny.chemgrid.org/
boxplotr/); whiskers extend 1.5 times the interquartile range from the 25th
and 75th percentiles, outliers are represented by dots. N= 5 sample points
for each data set.
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inhibit homotypic protein–protein contacts in heterodimers of
V127 and G127 PrP, or prevent the formation of extended β-sheet
structure required to convert the PrP N-terminal unstructured
region into protease-resistant β-enriched forms41,42,46,55.
Alternatively, the marked alteration in local backbone con-
formation and increased stability of intermolecular β-sheet
interactions may prevent PrP folding into a thermodynamically
permissible prion assembly3,4,56,57. As V127 PrP also inhibits the
generation of infectious assemblies of wild-type PrP, this would
suggest that it must be either capping nascent prion assemblies or
structurally weakening infectious prion assemblies on incor-
poration. The PMCA data presented here indicates that V127 PrP
is not a permissive substrate for amplification of protease-
resistant PrPSc disease seed. It is possible that the polymorphism
introduces a protease cleavage site, which would lead to the
destruction of a polymer formed of the homomeric V127 protein.
PrP V127 incorporation would also dope, with a dose-dependent
effect, heteromeric polymers composed of both G127 and V127
PrP variants. Their reduced stability could increase cellular
clearance, which would also explain the “dominant negative”
effect of V127 on prion propagation58.
In addition to these local structural perturbations, long-range
sequence interactions between the protective residue 127 and 129
polymorphisms affect the conformational distribution of a spa-
tially distinct region including the β-sheet, β2-α2 loop, the C-
terminus of helix 3 and the disease-associated residue D17837.
These conformationally variable elements have been shown to be
key determinants of prion transmission and cross-species prion
susceptibility, and a number are associated with inherited forms of
prion disease, for example G131V, D167N, V210I, E211Q, Q212P
and Q217R26,28,37,59–64. In particular, the β2-α2 loop (residues
165–172) has been proposed to be a key modulator of prion
transmission and disease-associated PrP misfolding26–28,35,36,58.
V127 alters the structural flexibility of the β-sheet and con-
formational dynamics of the β2-α2 loop by disrupting the elec-
trostatic interaction between R164 of the β-sheet and E168 within
the adjacent β2-α2 loop. Loss of this interaction would disrupt
hydrogen bonding and close packing between Y169, F175 and
D178 and destabilise the dominant 310–helical conformation of
the β2-α2 loop27,36,40 (Supplementary Figs. 11 and 12). Notably,
residue 168 (human numbering) is polymorphic in sheep PrP, in
which either glutamine or arginine can be accommodated65. The
arginine polymorph, which would also diminish the electrostatic
interaction with R164, is associated with resistance to scrapie, and
potently inhibits prion conversion60,62. These observations sup-
port the notion that increased conformational variability asso-
ciated with the loss of charge interaction between R164 and E168
increases resistance to prion disease. Substitution of arginine for
glutamine at the totally conserved Q172, the dynamics of which
are significantly altered in the V127 polymorph also potently
inhibits in vitro prion infectivity66.
The recent NMR structural study of V127 PrP also identified
significant alterations in the conformational dynamics in the β-
sheet and α-helix 2 as a result of the polymorphism34. Although
there are a number of residues perturbed in both studies, the
marked effect that we observe on the dynamics of the β2-α2 loop
was not observed in the previous study. The differences in protein
dynamics may be ascribed to the different solution conditions for
data acquisition. In this study PrP was crystallised at pH 8.0, with
the NMR solution dynamics acquired at pH 5.5, whereas the
previous NMR study used pH 4.5, which may cause glutamate
and aspartate side chains to adopt an unphysiological protonated
state34. The calculated pKa′s of E168 and D167 in V127/M129
PrP are 4.7 and 4.4, respectively67. The hydrogen-bonding and
charge interactions of the β2-α2 loop involving the side-chains of
these residues will be weakened through increased protonation.
This will likely cause altered conformational dynamics in the β2-
α2 loop and adjacent regions. For example, the lack of assigned
resonances for R164 by Zheng et al.34 may be ascribed to inter-
mediate timescale exchange broadening these signals beyond
detection. Given the pKa′s of interacting residues, the pH at which
structural studies are carried out might thus be very significant.
It is of great interest that both the V127 and V129 poly-
morphisms have long-range effects on the conformational dis-
tribution of these regions of the protein and also the β-sheet. The
correlation between these conformationally variable regions of
PrP and its propensity to form disease-related isoforms suggest
that these regions of the protein are important in prion assembly-
PrPC interactions, determining efficient binding and conver-
sion27,36. Indeed, relatively subtle variations in the strength and
orientation of monomer docking can dramatically affect the
productivity of fibrillogenic interactions and determine barriers to
amyloid formation68. Given the effect of the V127 polymorphism
on the PrP β-sheet backbone geometry and intermolecular
association of PrP monomers observed here, it is tempting to
speculate that dimerisation via the formation of the inter-
molecular PrP β-sheet may be a critical event in PrP oligomer-
isation and prion propagation and thus explain the exceptional
effect of the residue 127 polymorphism on human prion disease.
Methods
Recombinant PrP and antibodies. Recombinant human PrP containing residues
119–231 (PrP119–231) was produced and purified as previously described69. This
length of construct was chosen as the PrP N-terminus up to approximately residue
125 is unstructured in full-length (residues 23–231) and truncated (residues
91–231) PrP and compromises the NMR dynamics characterisation due to its effect
on the rotational tumbling of the structured domain70,71. Removal of the N-
terminal tail does not affect the structure or local structural fluctuations of the PrP
structured globular domain72,73. PrP containing valine at residue 127 (V127/M129
and V127/V129), and wild-type PrP with glycine at residue 127 on both 129
methionine and valine backgrounds (G127/M129 and G127/V129) were expressed
and purified for biophysical analysis. ICSM 18 was purchased from D-Gen Limited.
The Fab fragment of ICSM 18 was prepared by limited papain digest of the mature
antibody followed by purification using gel filtration chromatography.
Crystallisation conditions. ICSM 18-Fab and PrP were mixed at a molar ratio of
3:1 for preparation of the complex prior to crystallisation, and incubated at room
temperature for 30 min before buffer-exchanging the complex into 50 mM Tris,
150 mM NaCl, pH 8.0 and filtering through a 0.22 µm membrane prior to crys-
tallisation. Crystals of the complex were obtained by using the sitting-drop vapour
diffusion technique; droplets containing 5–6 mg/mL PrP in 0.4 M and 0.75 M
ammonium sulphate, 0.05 M Tris (pH 7.5 and 8.0) were equilibrated over wells
containing 0.8 M and 1.5 M ammonium sulphate, 0.1 M Tris (pH 7.5 and 8.0).
Crystals, round in shape, grew in 6 months to 0.05–0.2 mm diameter.
In situ data collection and analysis. Data were collected at room temperature
in situ on beamline I03 at Diamond Light Source, with the crystallisation plates
sealed in biohazard bags. Multiple wedges of data were collected from different
parts of the same crystal, and from different crystals, and scaled together to provide
a complete dataset. We typically collected 15° of data from each crystal in 0.3°
oscillations. Data were integrated with XDS74 and then subsequently BLEND75 was
used to analyse how well the different wedges of data scaled together and the results
used to decide which datasets should be scaled and merged with AIMLESS76.
Structure determination and refinement. The structures were solved by mole-
cular replacement using PHASER77 with the heavy and light chains of the Fab
fragment of antibody ICSM18 and the PrP molecule used as search models (protein
databank accession code 2W9E). Electron density maps were inspected and the
models built using COOT78 followed by refinement with REFMAC579. Data col-
lection and final refinement statistics are summarised in Supplementary Table 1.
Ramachandran statistics for V127/M129 and V127/V129 structures (in par-
entheses) are as follows; residues in most favoured region: 96.7% (96.7%), residues
in additionally allowed regions: 3.3% (3.3%) and residues in disallowed regions:
0.0% (0.0%)80. The final coordinates of the V127/M129 and V127/V129 structures
have been deposited in the Brookhaven Protein Data Bank (http://www.rcsb.org),
with accession numbers 6SV2 and 6SUZ respectively.
NMR sample preparation and spectroscopy. For the NMR study 15N & 13C/
15N-labelled samples of PrP were prepared. Following purification, protein samples
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were either (A) buffer-exchanged into 20 mM sodium acetate, containing 1.5 mM
sodium azide (NaN3), pH 5.5 through dialysis, then concentrated in Vivaspin 20
centrifugal concentrators to protein concentrations of 0.8–1.2 mM or (B) dialysed
against deionised water then lyophilised and resuspended into 20 mM sodium
acetate, 1.5 mM NaN3, pH 5.5. 10% D2O (v/v) was added to the NMR samples to
provide the lock signal, together with TSP as the chemical shift reference to 1 mM
final concentration. NMR samples were placed in Sigma FEP NMR sample tube
liners (Z286397–1EA), held within Wilmad PP-528 NMR tubes for NMR data
acquisition.
Assignment spectra for V127/M129 PrP were acquired at 303 K on Bruker
DRX-600 and DRX-800 spectrometers, with 15N-relaxation measurements for
V127 and V129 PrP acquired at 298 K on Bruker Avance III 500 and 800MHz
spectrometers, all equipped with 5 mm 13C/15N/1H triple-resonance probes.
Sensitivity-enhanced 1H-15N HSQC81,82 and standard triple-resonance
experiments83 with uniformly 13C/15N-labelled protein (HNCA, HNCACB, CBCA
(CO)NH and HNCO) were used to obtain V127/M129 backbone resonance
assignments. Proton chemical shifts were referenced to TSP. 13C & 15N chemical
shifts were calculated relative to TSP, using the gyromagnetic ratios of 13C, 15N and
1H (15N/1H= 0.101329118; 13C/1H= 0.251449530). For residue 127, when
comparing 13C chemical shifts, the difference in residue type was compensated for
by subtracting residue-specific random coil shifts (glycine/valine) to generate
secondary chemical shifts, which were then subtracted84. NMR data were processed
and analysed using Felix 2007 (Accelrys, San Diego), Topspin (v 3.2, Bruker) and
CCPN Analysis (v. 2.3.1)85 software.
Spin relaxation measurements. Spin relaxation measurements (T1, T2 and 15N
(1H)-NOE) were acquired on 1 mM 15N-labelled PrP119–231 WT (G127/M129)
PrP, V127 (V127/M129) PrP and V129 (G127/V129) PrP as described in Yip
et al.86. Briefly, by using this methodology, heating compensation was improved by
the incorporation of a compensation block based on the relaxation block, followed
by a pre-scan 1H saturation sequence and constant length recovery period. The T1
data were obtained using 15N relaxation delays of 50, 100, 200*, 300, 500, 800*,
1000, 1500, 2000, 3000, 4000 and 5000 ms. The T2 data were obtained using 15N
relaxation delays of 8.5, 17.0, 33.9*, 50.9, 67.8, 101.8*, 135.7, 186.6, 254.4 ms
(500MHz) and 7.8, 15.7, 31.4*, 47.0, 62.7*, 94.1, 125.4, 172.5 and 235.2 ms
(800MHz; the asterisks denote duplicate measurements). T1 and T2 datasets were
recorded as pseudo 3D experiments, with randomised order of time increments.
Two separate nitrogen offsets were used to reduce build-up of off-resonance
artefacts during the CPMG block of the T2 measurements. For the 15N-1H-NOE
measurement, two two-dimensional spectra were acquired with a relaxation delay
of 6 s between scans. Spectra were collected with t1 acquisition times of 94.7 ms
(500MHz)/59.2 ms (800MHz) and t2 (direct) acquisition times of 127.8 ms
(500MHz)/91.8 ms (800MHz). Errors for time-series T1 and T2 data were calcu-
lated from the overall standard deviation for duplicate data points in the series.
Errors for the NOE data were estimated from measurements of the root mean-
square deviation of the base-plane noise in those spectra. Non-linear least-squares
(Levenberg-Marquardt) fitting of two-parameter exponential functions to decay
data was performed using in-house routines using Numerical Python.
Modelfree analysis. Protein dynamics were analysed by Relax (v. 3.3.1)38,39, using
the T1, T2 and 15N{1H}-NOE spin relaxation data. Reduced spectral density
mapping analysis, as implemented by the Relax default J(w) mapping script mode
was used to obtain J(ω) values for each given field strength. A full Modelfree ana-
lysis87 was carried out using the “d’Auvergne” protocol within Relax. Extended
order parameters (S2, Sf2, Ss2), the effective correlation time for fast internal
motions (te) and intermediate exchange broadening contribution (Rex) values were
obtained using this protocol.
Amide exchange protection experiments. Hydrogen-deuterium exchange rates
(kex) were determined by adding 260 µl 20 mM sodium acetate, 1 mM sodium
azide, pH 4.5, dissolved in 100% (v/v) D2O to lyophilised PrP samples, to obtain
final protein concentrations of 1 mM. A series of sensitivity-enhanced 1H-15N
HSQC spectra81,82 were acquired at 293 K on a Bruker DRX-800 spectrometer. The
decay curves of the 1H-15N HSQC cross-peaks were fitted to single exponential
decays with offset, and protection factors (kex/kint) for observable amides were
determined using intrinsic amide exchange rates88 (kint). Acquisition of the first
experiment began ~5 min after mixing, setting a lower limit on the detection of
protection factors of ~5.
Circular dichroism. Circular dichroism was measured at 25 °C with a Jasco J-715
spectropolarimeter, using a 0.1 cm pathlength quartz cuvette. The sample tem-
perature was controlled with a circulating water bath. Far-UV (amide) CD spectra
were recorded between 180 nm and 300 nm with 20 μM protein (2 nm bandwidth;
Data Pitch 0.5 nm). In all, 10–50 spectra were averaged.
Equilibrium unfolding measurements. For equilibrium unfolding experiments, 6
μM protein was incubated in 10 mM HEPES, 25 mM NaCl pH 7.5, and increasing
concentrations of GuHCl denaturant. Molecular ellipticity ([θ], degree M−1 cm−1)
was recorded at 222 nm (5 nm bandwidth; 20 s integration time). The denaturation
profile for each protein was measured in three separate experiments.
Conversion to molar denaturant activity. To allow more accurate extrapolation
of data to calculate folding parameters in the absence of denaturant and the free
energy change of protein folding (ΔG), denaturant concentration ([GuHCl]) was
converted to molar denaturant activity (D), as described in Parker et al.89, using
C0.5= 7.5.
Equilibrium constant between folded and unfolded states. For the two-state
equilibrium unfolding transitions, data were fitted to the following equation, where
K and K(W) are equilibrium constants between the folded and unfolded states at a
given denaturant activity (D) and in water, respectively, and m describes the
sensitivity of the equilibrium to denaturant activity89.
K ¼ KðWÞexp m:Dð Þ ð1Þ
For visual representation of the data shown, data were converted to proportion
folded, αF, using the following, αF= (K/(1+ K)). Data fitting was carried out using
GraFit (Erithacus software). The significance of the differences in free energy for
folding and m values between the three variants characterised were determined by
paired two-tailed Student’s t test.
Quantitative analysis of the kinetics of PrP fibril formation. Recombinant
V127/M129 and WT G127/M129 PrP (residues 119–231) was dialysed into 20 mM
sodium acetate, 2 mM sodium azide, pH 6.0, and then denatured by the addition of
GuHCl to a final concentration of 6M. Denatured PrP was then diluted to a final
concentration of 10 µM in 20 mM sodium acetate, 2 M GuHCl, 10 mM EDTA, 100
µM Thioflavin T (ThT) and pH 6.0. All solutions were filtered through a 0.22-µm
filter to remove particulates. In all, 200 µl aliquots were placed in silanised Greiner
96-well flat-bottomed plates (#655077) containing four 0.5-mm diameter zirco-
nium ceramic beads in each well to assist agitation. The plates were incubated at
37 °C with constant agitation in a Tecan Infinite F200 Microplate Fluorimeter.
Fibril formation was monitored through the increase in ThT fluorescence (exci-
tation 430 nm, emission 485 nm), with readings acquired every 600 s. Five repli-
cates were used for each PrP sample.
To determine the half- and lag-times for fibril formation, data were fitted to an
empirical function described by Nielsen et al.90.
Fiþ Ff= 1þ exp  t  tmð Þ=τ½ f g ð2Þ
where Fi is the initial fluorescence reading, Ff is the final fluorescence reading, t is
time, tm is the time taken to half maximal fluorescence and τ is the reciprocal of the
propagation rate during the rise phase [1/k(apparent)]. Lag-time is defined as tm− 2τ.
Formation of protease-resistant PrP by PMCA amplification. PMCA substrate
homogenates were prepared from mice that had been perfused with PBS containing
5 mM EDTA at the time of death. PrP-null (Prnpo/o), Tg35 (homozygous for huPrP
G127/M129), Tg152 (homozygous for huPrP G127/V129) or Tg183 (homozygous
for huPrP V127/M129)) mouse brains25 were homogenised in cold conversion
buffer (PBS containing 150 mM NaCl, 1.0% (v/v) Triton X‐100, 4 mM EDTA and
1× Complete protease inhibitor (Roche Applied Science)), using a Duall tissue
grinder to give a 10% (w/v) homogenate.
Substrates were seeded with a 1/100 dilution of vCJD (I4618) 10% brain
homogenate in PBS. Each reaction mixture was divided in two prior to PMCA with
one half stored at −70 °C as a minus PMCA control. PMCA consisted of 96 cycles
of 30 s sonication every 30 min in a Misonix S3000 at 75% power output (Misonix,
Farmingdale, NY), reactions were carried out with 40 µl substrate in 200-µl thin-
walled PCR tubes at 35 °C.
Samples were digested with 50 µg ml−1 proteinase K (PK) for 1 h at 37 °C. The
reaction was stopped by the addition of AEBSF in SDS-loading buffer and samples
were boiled for 10 min before running on 16% Tris-glycine gels. Western blotting
was carried out according to Unit protocol, using 3F4 (Merck Inc, N.J., U.S.A) as
the primary antibody and goat anti-mouse IgG conjugated to alkaline phosphatase
(Sigma A2179) as the secondary antibody.
Statistics and reproducibility. In the reported experiments, each protein sample
was identically-engineered. The sample size (n) of each experiment is provided in
the corresponding figure captions in the main manuscript and supplementary
information files. Sample sizes were chosen to support meaningful conclusions. All
in vitro folding experiments were replicated at least three times. In vitro fibrilli-
sation assays were replicated five times. T1 and T2 NMR data were recorded with
randomised order of time increment and each included one duplicate dataset.
Replicate experiments were successful. Investigators were not blinded during
experimental measurements or data analysis.
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Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
The atomic coordinates for the crystal structures described in this paper have been
deposited in the Brookhaven Protein Data Bank (https://www.rcsb.org/) (accession nos.
6SV2 (V127/M129 PrP) & 6SUZ (V127/V129 PrP)). The data that support the findings
of this study are available from the corresponding author upon reasonable request.
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